세계의 지혈제 시장 규모, 점유율, 예측 및 동향 분석 : 유형별, 용도별, 최종사용자별 - 예측(-2031년)
Hemostats Market Size, Share, Forecast, & Trends Analysis by Type Form Application End User - Global Forecast to 2031
상품코드:1576516
리서치사:Meticulous Research
발행일:On Demand Report
페이지 정보:영문 280 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
지혈제 시장은 2024-2031년간 6.9%의 연평균 복합 성장률(CAGR)로 2031년 53억 2,000만 달러에 달할 것으로 예상됩니다.
이 보고서는 광범위한 2차 및 1차 조사, 시장 시나리오에 대한 심층 분석을 통해 주요 시장 성장 촉진요인, 억제요인, 과제 및 기회 분석으로 구성되어 있습니다. 이 시장의 성장은 암, 심혈관 질환, 정형외과 질환, 신경 질환과 같은 만성 질환의 유병률 증가와 그에 따른 수술 건수 증가, 사고율 증가, 제왕절개 분만 건수 증가, 치명적인 부상, 장기 이식, 연구 개발 활동 증가, 의료비 증가, 최소 침습적 수술에 대한 선호도 증가 등에 기인합니다. 증가에 기인합니다. 그러나 지혈제에 사용되는 재료로 인한 알레르기 반응은 이 시장의 성장을 저해하고 있습니다.
또한, 고급 지혈제의 사용 증가, 치과용 지혈제의 발전, 사전 로드된 도포기 및 RTU 지혈제에 대한 수요 증가는 이 시장에서 사업을 운영하는 기업들에게 성장 기회를 제공할 것으로 예상됩니다. 그러나 지혈제의 높은 제조 비용과 고급 항균 지혈제의 높은 비용은 시장 성장에 영향을 미치는 주요 과제입니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 시장 성장 요인
개요
성장 촉진요인
성장 억제요인
기회
과제
동향
요인 분석
규제 분석
가격 분석
사례 연구
Porter의 Five Forces 분석
제5장 지혈제 시장 평가 : 유형별
개요
흡수성 지혈제
기계적/수동적 지혈제
젤라틴 기반 지혈제
콜라겐 지혈제
산화 재생 셀룰로오스 지혈제
융동성 및 활성제
트롬빈계 지혈제
복합 지혈제
기타 흡수성 지혈제
비흡수성 지혈제
피브린 실란트
합성 실란트
지혈 가제
지혈 겸자
제6장 지혈제 시장 평가 : 용도별
개요
외과
정형외과
일반외과
부인과외과
심혈관외과
뇌신경외과
성형외과
기타 외과
치과 치료
외상
제7장 지혈제 시장 평가 : 형태별
개요
스펀지 및 드레싱
시트 및 패드
분말
매트릭스 및 겔
툴
제8장 지혈제 시장 평가 : 최종사용자별
개요
병원 및 진료소
외래수술센터(ASC)
요양시설
제9장 지혈제 시장 평가 : 지역별
개요
북미
미국
캐나다
유럽
독일
프랑스
영국
이탈리아
스페인
스위스
네덜란드
기타 유럽(RoE)
아시아태평양
일본
중국
인도
호주
한국
기타 아시아태평양(RoAPAC)
라틴아메리카
브라질
멕시코
기타 라틴아메리카(RoLATAM)
중동 및 아프리카
제10장 경쟁 분석
개요
주요 성장 전략
경쟁 벤치마킹
경쟁 대시보드
업계 리더
시장 차별화 요인
전위적 기업
신규 기업
주요 기업의 시장 점유율 분석/시장 순위(2023년)
제11장 기업 개요(사업 개요, 재무 개요, 제품 포트폴리오, 전략 전개 상황)
Baxter International Inc.(미국)
Pfizer Inc.(미국)
B. Braun Melsungen AG(독일)
C. R. Bard, Inc.(미국)
Integra LifeSciences(미국)
Medtronic plc(Ireland)
CSL Behring(영국)
Gelita Medical GmbH(독일)
Grifols, S.A.(Spain)
Abbott Laboratories(미국)
CryoLife(미국)
Ethicon, Inc.(미국)(Johnson & Johnson 자회사)
Medtronic plc(아일랜드)
Becton, Dickinson and Company(BD)(미국)
Advanced Medical Solutions Group plc(영국)
(주 : 주요 5개사의 SWOT 분석을 게재)
제12장 부록
LSH
영문 목차
영문목차
Hemostats Market Size, Share, Forecast, & Trends Analysis by Type (Gelatin, Collagen, Thrombin, Fibrin, Synthetic Sealant, Gauze) Form (Sheet, Powder, Gel) Application (Orthopedic, General, Cardiovascular, Dental, Trauma) End User- Global Forecast to 2031
The hemostat market is projected to reach $5.32 billion by 2031 at a CAGR of 6.9% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market can be attributed to the increasing prevalence of chronic diseases such as cancer, cardiovascular, orthopedic, and neurological diseases and subsequent increase in the volume of surgical procedures; increasing rate of accidents; rise in the number of cesarean deliveries, fatal injuries, and organ transplantation; increased R&D activities; rising healthcare spending; and growing preference for minimally invasive surgical procedures. However, allergic reactions caused by the material used in making hemostats restrain the growth of this market.
Furthermore, the increasing use of advanced hemostats, advancements in dental hemostatic agents, and increasing demand for preloaded applicators and ready-to-use hemostats are expected to generate growth opportunities for the players operating in this market. However, the high manufacturing cost for hemostasis and the high cost of advanced antimicrobial hemostatic agents are major challenges impacting market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the hemostat market are Baxter International Inc. (U.S.), Pfizer Inc. (U.S.), B. Braun Melsungen AG (Germany), C. R. Bard, Inc.(U.S.), Integra LifeSciences (U.S.), Medtronic plc (Ireland), CSL Behring (U.K.), Gelita Medical GmbH (Germany), Grifols, S.A. (Spain), Abbott Laboratories (U.S.), CryoLife (U.S.), Ethicon, Inc. (U.S.) (Subsidiary of Johnson & Johnson.), Medtronic plc (Ireland), Becton, Dickinson and Company (BD) (U.S.), and Advanced Medical Solutions Group plc (U.K.).
Among all the types studied in this report, in 2024, the absorbable hemostats segment is expected to account for the largest share of 58.6% of the hemostat market. The segment's large share is attributed to the advantages offered by absorbable hemostats, such as controlling bleeding from fistula-puncture sites, achieving hemostasis during vascular surgery, controlling capillary bleeding, availability of versatile forms of hemostats, and rapid embolization.
Among all the applications studied in this report, in 2024, the surgery segment is expected to account for the larger share of the hemostat market. The largest market share of this segment is attributed to the increasing number of surgeries, rise in the number of accidents, and growing demand for cosmetic/plastic surgeries. For instance, according to the World Health Organization (WHO), in 2021, yearly, 4.4 million people died from injuries, 3.16 million died from accidental wounds, and 1.25 million died from violence-related injuries globally.
Among all the forms studied in this report, in 2024, the matrix and gel segment is expected to account for the largest share of the hemostat market. The segment's large share is attributed to advantages offered by matrix and gel hemostatic agents, such as the formation of a physical matrix, promoting activation of the clotting pathway; their wide applications in patients with intact coagulation cascade; availability of bioactive and biocompatible gels; and cost efficiency.
Among all the end users studied in this report, in 2024, the hospitals & clinics segment is expected to account for the largest share of the hemostat market. The growing number of surgeries conducted in hospitals, the use of hemostats for control of minor, moderate, and severe bleeding in operating rooms, the availability of different forms of hemostats used for surgical procedures, and the availability of favorable reimbursement policies are some of the major factors driving the growth of this segment.
An in-depth analysis of the geographical scenario of the hemostat market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 32.9% of the hemostat market. In the region in 2024, the U.S. is expected to account for the largest share of the hemostat market in North America. The large share of this regional market is attributed to the presence of key market players in the U.S., a well-established and technologically advanced healthcare infrastructure, and favorable government policies in the country.
Scope of the Report:
Hemostat Market Assessment-by Type
Absorbable Hemostats
Mechanical or Passive Agents
Gelatin-based Hemostat
Collagen Hemostat
Oxidized Regenerated Cellulose Hemostat
Flowable and Active Agents
Thrombin-based Hemostat
Combination Hemostat
Other Absorbable Hemostat
Non-absorbable Hemostats
Fibrin Sealants
Synthetic Sealants
Hemostatic Gauze
Hemostatic Forceps
Hemostat Market Assessment-by Application
Surgery
Orthopedic Surgery
General Surgery
Gynecology Surgery
Cardiovascular Surgery
Neurosurgery
Plastic Surgery
Other Surgeries
Dental Treatments
Traumatic Injury
Hemostat Market Assessment-by Form
Sponges and Dressings
Sheets and Pads
Powder
Matrix and Gel
Tools
Hemostat Market Assessment-by End User
Hospitals & Clinics
Ambulatory Surgical Centers
Nursing Homes
Hemostat Market Assessment-by Geography
North America
U.S.
Canada
Europe
Germany
France
U.K
Italy
Spain
Switzerland
Netherlands
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
TABLE OF CONTENTS
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Data Collection and Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Factors Affecting Market Growth
4.1. Overview
4.2. Drivers
4.2.1. Increasing Volume of Surgical Procedures Performed
4.2.2. High Research and Development in Surgical Devices Sector
4.2.3. Increasing Rate of Accidents
4.2.4. Increase in Cesarean Deliveries, Fatal Injuries, and Organ Transplantation
4.2.5. Increasing R&D Activities by Government Organizations and the Private Sector
4.2.6. Rising Government Healthcare Spending
4.2.7. Growing Adoption of Minimally Invasive Surgical Procedures
4.3. Restraints
4.3.1. Allergic Reactions Caused by the Material Used in Making Hemostats
4.4. Opportunities
4.4.1. Increasing Need to Control Blood Loss by Using Advanced Hemostats
4.4.2. Advancements in Dental Hemostatic Agents
4.4.3. Increasing Demand for Preloaded Applicators and Ready-to-Use Hemostats
4.5. Challenges
4.5.1. High Manufacturing Cost for Hemostasis
4.5.2. High Cost of Advanced Antimicrobial Hemostatic Agents
4.6. Trends
4.6.1. Biopolymer-based Hemostats
4.6.2. Dual-Action Hemostatic Technology
4.7. Factor Analysis
4.8. Regulatory Analysis
4.9. Pricing Analysis
4.10. Case Studies
4.11. Porter's Five Forces Analysis
5. Hemostats Market Assessment-by Type
5.1. Overview
5.2. Absorbable Hemostats
5.2.1. Mechanical or Passive Agents
5.2.1.1. Gelatin-based Hemostat
5.2.1.2. Collagen Hemostat
5.2.1.3. Oxidized Regenerated Cellulose Hemostat
5.2.2. Flowable and Active Agents
5.2.2.1. Thrombin-based Hemostat
5.2.2.2. Combination Hemostat
5.2.3. Other Absorbable Hemostats
5.3. Non-absorbable Hemostats
5.3.1. Fibrin Sealants
5.3.2. Synthetic Sealants
5.3.3. Hemostatic Gauze
5.3.4. Hemostatic Forceps
6. Hemostats Market Assessment-by Application
6.1. Overview
6.2. Surgery
6.2.1. Orthopedic Surgery
6.2.2. General Surgery
6.2.3. Gynecology Surgery
6.2.4. Cardiovascular Surgery
6.2.5. Neurosurgery
6.2.6. Plastic Surgery
6.2.7. Other Surgeries
6.3. Dental Treatments
6.4. Traumatic Injury
7. Hemostats Market Assessment-by Form
7.1. Overview
7.2. Sponges and Dressings
7.3. Sheets and Pads
7.4. Powder
7.5. Matrix and Gel
7.6. Tools
8. Hemostats Market Assessment-by End User
8.1. Overview
8.2. Hospitals & Clinics
8.3. Ambulatory Surgical Centers
8.4. Nursing Homes
9. Hemostats Market Assessment-by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Switzerland
9.3.7. Netherlands
9.3.8. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5 South Korea
9.4.6. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America (RoLATAM)
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis/Market Rankings of Key Players (2023)
11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. Baxter International Inc. (U.S.)
11.2. Pfizer Inc. (U.S.)
11.3. B. Braun Melsungen AG (Germany)
11.4. C. R. Bard, Inc.(U.S.)
11.5. Integra LifeSciences (U.S.)
11.6. Medtronic plc (Ireland)
11.7. CSL Behring (U.K.)
11.8. Gelita Medical GmbH (Germany)
11.9. Grifols, S.A. (Spain)
11.10. Abbott Laboratories (U.S.)
11.11. CryoLife (U.S.)
11.12. Ethicon, Inc. (U.S.) (a subsidiary of Johnson & Johnson.)
11.13. Medtronic plc (Ireland)
11.14. Becton, Dickinson and Company (BD) (U.S.)
11.15. Advanced Medical Solutions Group plc (U.K.)
(Note: SWOT analysis of the top 5 companies will be provided.)
